Versarien plc (LON:VRS), the advanced materials engineering group, is pleased to announce that it has signed an agreement to develop a range of graphene based sensor technologies to enable the creation of digital bandages and wound dressings capable of various forms of physiological movement and excretion detection.
This project will utilise strain sensors printed with graphene ink using methods which have been developed by the Company’s subsidiary, Cambridge Graphene Limited. Trials will take place at the internationally renowned Addenbrooke’s Hospital in Cambridge with Orthopaedic surgeon Dr Arman Memanzedah leading the clinical trials. He will be joined by Dr Simon Rudland from Stowhealth who will be working with the team to optimise the usability of the data from the graphene dressings to ensure the optimal recovery of the patients post discharge. The agreement will also involve Dr Chris Crockford, Managing Director of Digital and Future Technologies Limited, who will act as liaison between the hospital, Versarien and wider global providers in this field.
Neill Ricketts, CEO of Versarien Plc, commented: “We are very pleased to be working to bring our graphene ink technology to the medical arena. This is our first collaboration in this area and we anticipate that the properties of the high quality graphene we produce can bring significant benefits. In particular, the incorporation of graphene inks will enable the development of ‘smart’ wound dressings, facilitating better patient monitoring and enhanced recovery.
“We are very excited about the potential for graphene in a variety of medical uses and anticipate entering into further collaborations in this area in due course.”